Gastric bypass leads to improvement of diabetic neuropathy independent of glucose normalization: results of a prospective cohort study (diasurg 1 study)

B.P. Müller-Stich; L. Fischer; H.G. Kenngott; Matthias Gondan; J. Senft; G. Clemens; F. Nickel; T. Fleming; P.P. Nawroth; M.W. Büchler

doi:10.1097/sla.0b013e3182a618b2

Gastric bypass leads to improvement of diabetic neuropathy independent of glucose normalization: results of a prospective cohort study (diasurg 1 study)

B.P. Müller-Stich, L. Fischer, H.G. Kenngott, Matthias Gondan, J. Senft, G. Clemens, F. Nickel, T. Fleming, P.P. Nawroth, M.W. Büchler

46 Citations (Scopus)

Abstract

Objective: Surprisingly, 40% to 95% of patients with type 2 diabetes mellitus (T2DM) show early remission of hyperglycemia after obesity surgery. It is unknown to what extent other diabetes-associated comorbidities such as distal peripheral neuropathy (DPN) might be influenced by obesity surgery. This pilot study aimed at providing further evidence for the impact of Roux-en-Y gastric bypass (RYGB) on both glycemic control and DPN in nonseverely obese patients with insulin-dependent T2DM. Methods: In the present prospective cohort study, 20 patients with long-standing, insulin-dependent T2DM and a body mass index (BMI) between 25 and 35 kg/m underwent laparoscopic RYGB. Body mass index, glycosylated hemoglobin (HbA1c), and DPN [quantified by the Neuropathy Symptom Score (NSS) and the Neuropathy Deficit Score (NDS)] were investigated. Results: Six months after surgery, the preoperative BMI of 32.8 ± 2.1 kg/m ² (mean ± standard deviation) dropped to 25.6 ± 2.5 kg/m² (P < 0.001). Preoperative HbA_1c levels decreased from 8.5 ± 1.2% to 7.1 ± 1.2% (P < 0.001), with 15% of patients having a normalized HbA_1c level lower than 6.2%. Of 12 patients with documented DPN, the median NSS was 8 (range, 0-10) preoperatively and 0 (range, 0-9) postoperatively (P = 0.004), with 8 patients scoring an NSS of 0. The median NDS was 6 (range, 2-8) preoperatively and 4 (range, 0-8) postoperatively (P = 0.027), with 1 patient scoring an NDS of 0. All patients had an improvement or normalization in either 1 or both scores. Conclusions: As expected, BMI and HbA1c levels improved significantly after RYGB. More interestingly, neuropathy scores, such as NSS and NDS, improved significantly early after surgery. Symptomatic neuropathy was completely reversible in 67% of the patients. These findings add further evidence to the fact that RYGB might be a valuable treatment option not only for improving glycemic control but also for reducing diabetes-associated comorbidities, such as DPN. This points to a complex metabolic effect of RYGB that exceeds glucose normalization. However, the results still need to be confirmed in controlled trials.

Original language	English
Journal	Annals of Surgery
Volume	258
Issue number	5
Pages (from-to)	760–766
Number of pages	7
ISSN	0003-4932
DOIs	https://doi.org/10.1097/sla.0b013e3182a618b2
Publication status	Published - Nov 2013

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1097/sla.0b013e3182a618b2

Cite this

Müller-Stich, B. P., Fischer, L., Kenngott, H. G., Gondan, M., Senft, J., Clemens, G., Nickel, F., Fleming, T., Nawroth, P. P., & Büchler, M. W. (2013). Gastric bypass leads to improvement of diabetic neuropathy independent of glucose normalization: results of a prospective cohort study (diasurg 1 study). Annals of Surgery, 258(5), 760–766. https://doi.org/10.1097/sla.0b013e3182a618b2

Müller-Stich, BP, Fischer, L, Kenngott, HG, Gondan, M, Senft, J, Clemens, G, Nickel, F, Fleming, T, Nawroth, PP & Büchler, MW 2013, 'Gastric bypass leads to improvement of diabetic neuropathy independent of glucose normalization: results of a prospective cohort study (diasurg 1 study)', Annals of Surgery, vol. 258, no. 5, pp. 760–766. https://doi.org/10.1097/sla.0b013e3182a618b2

@article{0b0f8513a70f4613b88b07c927067bbc,

title = "Gastric bypass leads to improvement of diabetic neuropathy independent of glucose normalization: results of a prospective cohort study (diasurg 1 study)",

abstract = "Objective: Surprisingly, 40% to 95% of patients with type 2 diabetes mellitus (T2DM) show early remission of hyperglycemia after obesity surgery. It is unknown to what extent other diabetes-associated comorbidities such as distal peripheral neuropathy (DPN) might be influenced by obesity surgery. This pilot study aimed at providing further evidence for the impact of Roux-en-Y gastric bypass (RYGB) on both glycemic control and DPN in nonseverely obese patients with insulin-dependent T2DM. Methods: In the present prospective cohort study, 20 patients with long-standing, insulin-dependent T2DM and a body mass index (BMI) between 25 and 35 kg/m underwent laparoscopic RYGB. Body mass index, glycosylated hemoglobin (HbA1c), and DPN [quantified by the Neuropathy Symptom Score (NSS) and the Neuropathy Deficit Score (NDS)] were investigated. Results: Six months after surgery, the preoperative BMI of 32.8 ± 2.1 kg/m 2 (mean ± standard deviation) dropped to 25.6 ± 2.5 kg/m2 (P < 0.001). Preoperative HbA1c levels decreased from 8.5 ± 1.2% to 7.1 ± 1.2% (P < 0.001), with 15% of patients having a normalized HbA1c level lower than 6.2%. Of 12 patients with documented DPN, the median NSS was 8 (range, 0-10) preoperatively and 0 (range, 0-9) postoperatively (P = 0.004), with 8 patients scoring an NSS of 0. The median NDS was 6 (range, 2-8) preoperatively and 4 (range, 0-8) postoperatively (P = 0.027), with 1 patient scoring an NDS of 0. All patients had an improvement or normalization in either 1 or both scores. Conclusions: As expected, BMI and HbA1c levels improved significantly after RYGB. More interestingly, neuropathy scores, such as NSS and NDS, improved significantly early after surgery. Symptomatic neuropathy was completely reversible in 67% of the patients. These findings add further evidence to the fact that RYGB might be a valuable treatment option not only for improving glycemic control but also for reducing diabetes-associated comorbidities, such as DPN. This points to a complex metabolic effect of RYGB that exceeds glucose normalization. However, the results still need to be confirmed in controlled trials.",

author = "B.P. M{\"u}ller-Stich and L. Fischer and H.G. Kenngott and Matthias Gondan and J. Senft and G. Clemens and F. Nickel and T. Fleming and P.P. Nawroth and M.W. B{\"u}chler",

year = "2013",

month = nov,

doi = "10.1097/sla.0b013e3182a618b2",

language = "English",

volume = "258",

pages = "760–766",

journal = "Advances in Surgery",

issn = "0003-4932",

publisher = "Lippincott Williams & Wilkins",

number = "5",

}

TY - JOUR

T1 - Gastric bypass leads to improvement of diabetic neuropathy independent of glucose normalization

T2 - results of a prospective cohort study (diasurg 1 study)

AU - Müller-Stich, B.P.

AU - Fischer, L.

AU - Kenngott, H.G.

AU - Gondan, Matthias

AU - Senft, J.

AU - Clemens, G.

AU - Nickel, F.

AU - Fleming, T.

AU - Nawroth, P.P.

AU - Büchler, M.W.

PY - 2013/11

Y1 - 2013/11

N2 - Objective: Surprisingly, 40% to 95% of patients with type 2 diabetes mellitus (T2DM) show early remission of hyperglycemia after obesity surgery. It is unknown to what extent other diabetes-associated comorbidities such as distal peripheral neuropathy (DPN) might be influenced by obesity surgery. This pilot study aimed at providing further evidence for the impact of Roux-en-Y gastric bypass (RYGB) on both glycemic control and DPN in nonseverely obese patients with insulin-dependent T2DM. Methods: In the present prospective cohort study, 20 patients with long-standing, insulin-dependent T2DM and a body mass index (BMI) between 25 and 35 kg/m underwent laparoscopic RYGB. Body mass index, glycosylated hemoglobin (HbA1c), and DPN [quantified by the Neuropathy Symptom Score (NSS) and the Neuropathy Deficit Score (NDS)] were investigated. Results: Six months after surgery, the preoperative BMI of 32.8 ± 2.1 kg/m 2 (mean ± standard deviation) dropped to 25.6 ± 2.5 kg/m2 (P < 0.001). Preoperative HbA1c levels decreased from 8.5 ± 1.2% to 7.1 ± 1.2% (P < 0.001), with 15% of patients having a normalized HbA1c level lower than 6.2%. Of 12 patients with documented DPN, the median NSS was 8 (range, 0-10) preoperatively and 0 (range, 0-9) postoperatively (P = 0.004), with 8 patients scoring an NSS of 0. The median NDS was 6 (range, 2-8) preoperatively and 4 (range, 0-8) postoperatively (P = 0.027), with 1 patient scoring an NDS of 0. All patients had an improvement or normalization in either 1 or both scores. Conclusions: As expected, BMI and HbA1c levels improved significantly after RYGB. More interestingly, neuropathy scores, such as NSS and NDS, improved significantly early after surgery. Symptomatic neuropathy was completely reversible in 67% of the patients. These findings add further evidence to the fact that RYGB might be a valuable treatment option not only for improving glycemic control but also for reducing diabetes-associated comorbidities, such as DPN. This points to a complex metabolic effect of RYGB that exceeds glucose normalization. However, the results still need to be confirmed in controlled trials.

AB - Objective: Surprisingly, 40% to 95% of patients with type 2 diabetes mellitus (T2DM) show early remission of hyperglycemia after obesity surgery. It is unknown to what extent other diabetes-associated comorbidities such as distal peripheral neuropathy (DPN) might be influenced by obesity surgery. This pilot study aimed at providing further evidence for the impact of Roux-en-Y gastric bypass (RYGB) on both glycemic control and DPN in nonseverely obese patients with insulin-dependent T2DM. Methods: In the present prospective cohort study, 20 patients with long-standing, insulin-dependent T2DM and a body mass index (BMI) between 25 and 35 kg/m underwent laparoscopic RYGB. Body mass index, glycosylated hemoglobin (HbA1c), and DPN [quantified by the Neuropathy Symptom Score (NSS) and the Neuropathy Deficit Score (NDS)] were investigated. Results: Six months after surgery, the preoperative BMI of 32.8 ± 2.1 kg/m 2 (mean ± standard deviation) dropped to 25.6 ± 2.5 kg/m2 (P < 0.001). Preoperative HbA1c levels decreased from 8.5 ± 1.2% to 7.1 ± 1.2% (P < 0.001), with 15% of patients having a normalized HbA1c level lower than 6.2%. Of 12 patients with documented DPN, the median NSS was 8 (range, 0-10) preoperatively and 0 (range, 0-9) postoperatively (P = 0.004), with 8 patients scoring an NSS of 0. The median NDS was 6 (range, 2-8) preoperatively and 4 (range, 0-8) postoperatively (P = 0.027), with 1 patient scoring an NDS of 0. All patients had an improvement or normalization in either 1 or both scores. Conclusions: As expected, BMI and HbA1c levels improved significantly after RYGB. More interestingly, neuropathy scores, such as NSS and NDS, improved significantly early after surgery. Symptomatic neuropathy was completely reversible in 67% of the patients. These findings add further evidence to the fact that RYGB might be a valuable treatment option not only for improving glycemic control but also for reducing diabetes-associated comorbidities, such as DPN. This points to a complex metabolic effect of RYGB that exceeds glucose normalization. However, the results still need to be confirmed in controlled trials.

UR - http://www.scopus.com/inward/record.url?scp=84882483226&partnerID=8YFLogxK

U2 - 10.1097/sla.0b013e3182a618b2

DO - 10.1097/sla.0b013e3182a618b2

M3 - Journal article

C2 - 23979278

SN - 0003-4932

VL - 258

SP - 760

EP - 766

JO - Advances in Surgery

JF - Advances in Surgery

IS - 5

ER -

Gastric bypass leads to improvement of diabetic neuropathy independent of glucose normalization: results of a prospective cohort study (diasurg 1 study)

Abstract

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this